Imaging endpoints for clinical trials in Alzheimer’s disease
Open Access
- 20 December 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Alzheimer's Research & Therapy
- Vol. 6 (9), 1-10
- https://doi.org/10.1186/s13195-014-0087-9
Abstract
As the need to develop a successful disease-modifying treatment for Alzheimer’s disease (AD) becomes more urgent, imaging is increasingly used in therapeutic trials. We provide an overview of how the different imaging modalities are used in AD studies and the current regulatory guidelines for their use in clinical trials as endpoints. We review the current literature for results of imaging endpoints of efficacy and safety in published clinical trials. We start with trials in mild to moderate AD, where imaging (largely magnetic resonance imaging (MRI)) has long played a role in inclusion and exclusion criteria; more recently, MRI has been used to identify adverse events and to measure rates of brain atrophy. The advent of amyloid imaging using positron emission tomography has led to trials incorporating amyloid measurements as endpoints and incidentally to the recognition of the high proportion of amyloid-negative individuals that may be recruited into these trials. Ongoing and planned trials now commonly include multimodality imaging: amyloid positron emission tomography, MRI and other modalities. At the same time, the failure of recent large profile trials in mild to moderate AD together with the realisation that there is a long prodromal period to AD has driven a push to move studies to earlier in the disease. Imaging has particularly important roles, alongside other biomarkers, in assessing efficacy because conventional clinical outcomes may have limited ability to detect treatment effects in these early stages.Keywords
This publication has 72 references indexed in Scilit:
- Unbiased tensor-based morphometry: Improved robustness and sample size estimates for Alzheimer's disease clinical trialsNeuroImage, 2013
- The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inceptionAlzheimer's & Dementia, 2011
- Unbiased comparison of sample size estimates from longitudinal structural measures in ADNIHuman Brain Mapping, 2011
- Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCINeurobiology of Aging, 2011
- Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's diseaseNeuroImage, 2010
- Alzheimer's disease: clinical trials and drug developmentThe Lancet Neurology, 2010
- The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomesAlzheimer's & Dementia, 2010
- PET imaging of amyloid deposition in patients with mild cognitive impairmentNeurobiology of Aging, 2008
- Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humansAnnals of Neurology, 2006
- MRI as a biomarker of disease progression in a therapeutic trial of milameline for ADNeurology, 2003